NCT07189377RecruitingPhase 4
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
Lung Transplantation Using Hepatitis B Positive Donors to Hepatitis B Negative Recipients Using Ex-Vivo Treatment of Organs: A Safety Trial
Source: ClinicalTrials.gov · Last updated 17 Nov 2025
Brief summary (registry, in English)
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 9 Sept 2025
- Start date
- 24 Sept 2025
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Hepatitis B
- NCT number
- NCT07189377
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 20
- From 24 Sept 2025 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Donor Inclusion Criteria
- Donor lung suitable for transplantation
- HBV SAg positive and/or HBV NAT+ donor
- Donor Exclusion Criteria
- HIV positive
- HTLV 1/2 positive;
- Any medical issues in the donor that would normally clinically exclude the donor (e.g. history of cancer, evidence of organ dysfunction, etc).
- Recipient inclusion Criteria:
- Recipients eligible and listed for lung transplant
- HBV NAT negative
- Provides written informed consent
- Has received at least 3 prior doses of Hepatitis B vaccine or anti-HBs\>=10 IU/mL
- Patients with other co-morbid conditions (such as diabetes, autoimmune disease, renal dysfunction) will remain eligible provided they are otherwise medically suitable for transplantation. The exception to this will be patients with significant liver disease as outlined below.
- Recipient exclusion Criteria:
- Chronic liver disease with \> stage 2 fibrosis
- Participating in another interventional clinical trial
- Recipient listed for combined transplant (e.g., heart-lung, lung-liver)
- Known allergy or contraindication to any of the antiviral medications
- Hepatitis B surface antigen (HBsAg) or Hepatitis B core Ab positive pre-transplant (indicates already HBV infected).
- HIV positive
- Patients with a low level of serum IgA pre-transplant (this may be a risk factor for sensitivity reaction to HBIG).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Health Network, Toronto General Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.